Trademark: 79331138
Word
CEBEXAN
Status
Dead
Status Code
602
Status Date
Thursday, January 12, 2023
Serial Number
79331138
Mark Type
3000
Filing Date
Thursday, September 23, 2021
Abandoned Date
Tuesday, January 3, 2023

Trademark Owner History

Classifications
5 Pharmaceutical preparations; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances; pharmaceutical preparations and substances for use in urology; pharmaceutical preparations and substances for use in gynaecology; pharmaceutical preparations and substances for use in the field of anaesthesia; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances with analgesic properties; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances with anti-inflammatory properties; pharmaceutical preparations and substances with antipyretic properties; pharmaceutical anti-allergic preparations and substances; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for treating chemical imbalances; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for treating allergic rhinitis; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for treating allergies; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for treating skin diseases; pharmaceutical preparations for treating wounds; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the treatment of worms in pets; pharmaceutical preparations for peripheral nervous system; pharmaceutical preparations for use in dermatology; pharmaceutical preparations against dry skin caused by pregnancy; pharmaceutical preparations for treating chloasma; pharmaceutical preparations for activating cellular functions; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for skin moisturizing during pregnancy; pharmaceutical preparations for adapting immunity; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations to prevent stretch marks; pharmaceutical preparations for preventing skin blemishes during pregnancy; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for treating Parkinson's disease; pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating sports related injuries; pharmaceutical preparations for treating cardiac arrhythmias; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of viral diseases; pharmaceutical preparations for the treatment of digestive diseases; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the relief of insect bites; pharmaceutical preparations for human use; pharmaceutical preparations for treating eye diseases and conditions; pharmaceutical preparations for treating multiple sclerosis; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the prevention of bacteria-based diseases; pharmaceutical preparations to prevent allergies; pharmaceutical preparations for the prevention of inflammatory diseases; pharmaceutical preparations for the prevention immune system related disorders; pharmaceutical preparations for the treatment of bacteria-based diseases; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the prevention of musculoskeletal diseases; pharmaceutical preparations for the prevention of diseases of the nervous system pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of endocrine system related disorders; pharmaceutical preparations for the prevention of immune system related diseases; pharmaceutical preparations for the treatment of metabolic system related diseases; pharmaceutical preparations for the prevention of the metabolic system related disorders; pharmaceutical preparations for the treatment of metabolic system related disorders; pharmaceutical preparations for the prevention of endocrine system related disorders; pharmaceutical preparations for the treatment of genitourinary system related disorders; pharmaceutical preparations for the prevention genitourinary system related disorders; pharmaceutical preparations for the prevention of metabolic system related diseases; pharmaceutical preparations for the treatment of endocrine system related diseases; pharmaceutical preparations for the prevention of respiratory system related disorders; pharmaceutical preparations for the prevention of musculoskeletal system related diseases; pharmaceutical preparations for use in organ transplantation; pharmaceutical preparations for skin wounds; hair care pharmaceutical preparations; pharmaceutical preparations for treating esophagitis; pharmaceutical preparations for the prevention of ocular disorders; pharmaceutical preparations for the treatment of genitourinary system related diseases; pharmaceutical preparations for use in tissue transplantation; pharmaceutical preparations for the treatment of bacteria-based disorders; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the prevention of bacteria-based disorders; pharmaceutical preparations for the prevention of inflammatory disorders; pharmaceutical preparations for use in haematology; pharmaceutical preparations for the prevention of respiratory diseases; pharmaceutical preparations for the prevention of endocrine system related diseases; pharmaceutical preparations for the prevention of eye diseases; pharmaceutical preparations for the prevention of genitourinary system related diseases; pharmaceutical preparations for ear diseases; pharmaceutical preparations for treating epilepsy; pharmaceutical preparations for treating hypoglycaemia; pharmaceutical preparations for inhalers; pharmaceutical preparations for treating epidermal problems; pharmaceutical preparations for treating metabolism disorders; pharmaceutical preparations for treating halitosis; pharmaceutical preparations for the treatment of digestive system related diseases; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of sensory organs diseases; pharmaceutical preparations for the treatment of radiation sickness symptoms; pharmaceutical preparations for the treatment of skeletal diseases; pharmaceutical preparations for treating rheumatic diseases; pharmaceutical preparations for treating arthritis; pharmaceutical products for injection; pharmaceutical products for the prevention of autoimmune diseases; pharmaceutical products for the treatment of kidney diseases; pharmaceutical products for the prevention of diabetes; pharmaceutical products for ophthalmological use; pharmaceutical products for the treatment of autoimmune diseases; pharmaceutical products for the treatment of kidney diseases; pharmaceutical products for smoking cessation; pharmaceutical products for inducing erection; pharmaceutical products for the treatment of erectile dysfunction; pharmaceutical products for animal skincare; pharmaceutical products against diabetes; pharmaceutical products against bacteria; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of musculoskeletal diseases; pharmaceutical preparations for the treatment of hypercholesterolemia; pharmaceutical products for treating depression; pharmaceutical products for ocular use; pharmaceutical compositions; pharmaceutical moisturizing body lotion
The colors black, green and blue are claimed as a feature of the mark.
The wording "CEBEXAN" has no meaning in a foreign language.

Trademark Events
Feb 5, 2024
Final Decision Transaction Processed By Ib
Jan 12, 2024
Final Disposition Notice Sent To Ib
Jan 12, 2024
Final Disposition Notice Created, To Be Sent To Ib
Jul 3, 2023
Notification Of Possible Opposition - Processed By Ib
Jun 14, 2023
Notification Of Possible Opposition Sent To Ib
Jun 14, 2023
Notification Of Possible Opposition Created, To Be Sent To Ib
Jan 12, 2023
Abandonment Notice Mailed - Failure To Respond
Jan 12, 2023
Abandonment Notice Mailed - Failure To Respond
Jan 12, 2023
Abandonment - Failure To Respond Or Late Response
Jul 19, 2022
Refusal Processed By Ib
Jun 30, 2022
Non-Final Action Mailed - Refusal Sent To Ib
Jun 30, 2022
Refusal Processed By Mpu
Jun 29, 2022
Non-Final Action (Ib Refusal) Prepared For Review
Jun 28, 2022
Non-Final Action Written
Jun 25, 2022
Assigned To Examiner
Jan 22, 2022
Application Filing Receipt Mailed
Jan 18, 2022
New Application Office Supplied Data Entered
Jan 13, 2022
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24